nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—ALB—Estropipate—osteoporosis	0.151	0.327	CbGbCtD
Gliclazide—CYP2C9—Estropipate—osteoporosis	0.0812	0.176	CbGbCtD
Gliclazide—ALB—Estradiol—osteoporosis	0.0625	0.136	CbGbCtD
Gliclazide—CYP2C19—Cholecalciferol—osteoporosis	0.0503	0.109	CbGbCtD
Gliclazide—CYP2C9—Cholecalciferol—osteoporosis	0.0418	0.0908	CbGbCtD
Gliclazide—CYP2C19—Estradiol—osteoporosis	0.0405	0.088	CbGbCtD
Gliclazide—CYP2C9—Estradiol—osteoporosis	0.0337	0.0732	CbGbCtD
Gliclazide—VEGFA—Estradiol—Estropipate—osteoporosis	0.00248	0.418	CbGdCrCtD
Gliclazide—VEGFA—Estradiol—Conjugated Estrogens—osteoporosis	0.00188	0.317	CbGdCrCtD
Gliclazide—VEGFA—Estradiol—Ethinyl Estradiol—osteoporosis	0.00158	0.266	CbGdCrCtD
Gliclazide—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000209	0.000558	CcSEcCtD
Gliclazide—Asthenia—Estropipate—osteoporosis	0.000208	0.000556	CcSEcCtD
Gliclazide—Visual impairment—Estradiol—osteoporosis	0.000208	0.000556	CcSEcCtD
Gliclazide—Arthralgia—Zoledronate—osteoporosis	0.000208	0.000555	CcSEcCtD
Gliclazide—Chest pain—Zoledronate—osteoporosis	0.000208	0.000555	CcSEcCtD
Gliclazide—Myalgia—Zoledronate—osteoporosis	0.000208	0.000555	CcSEcCtD
Gliclazide—Palpitations—Conjugated Estrogens—osteoporosis	0.000208	0.000555	CcSEcCtD
Gliclazide—Insomnia—Risedronate—osteoporosis	0.000208	0.000554	CcSEcCtD
Gliclazide—Anxiety—Zoledronate—osteoporosis	0.000207	0.000553	CcSEcCtD
Gliclazide—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000207	0.000552	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000206	0.000551	CcSEcCtD
Gliclazide—Paraesthesia—Risedronate—osteoporosis	0.000206	0.00055	CcSEcCtD
Gliclazide—Pruritus—Estropipate—osteoporosis	0.000205	0.000548	CcSEcCtD
Gliclazide—Discomfort—Zoledronate—osteoporosis	0.000205	0.000548	CcSEcCtD
Gliclazide—Asthenia—Alendronate—osteoporosis	0.000205	0.000548	CcSEcCtD
Gliclazide—Hypersensitivity—Ibandronate—osteoporosis	0.000205	0.000548	CcSEcCtD
Gliclazide—Cough—Conjugated Estrogens—osteoporosis	0.000205	0.000548	CcSEcCtD
Gliclazide—Dyspnoea—Risedronate—osteoporosis	0.000205	0.000546	CcSEcCtD
Gliclazide—Erythema multiforme—Estradiol—osteoporosis	0.000204	0.000546	CcSEcCtD
Gliclazide—Hypotension—Pamidronate—osteoporosis	0.000204	0.000544	CcSEcCtD
Gliclazide—Convulsion—Conjugated Estrogens—osteoporosis	0.000204	0.000544	CcSEcCtD
Gliclazide—Dry mouth—Zoledronate—osteoporosis	0.000203	0.000543	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000203	0.000542	CcSEcCtD
Gliclazide—Fatigue—Ethinyl Estradiol—osteoporosis	0.000203	0.000542	CcSEcCtD
Gliclazide—Pruritus—Alendronate—osteoporosis	0.000202	0.00054	CcSEcCtD
Gliclazide—Dyspepsia—Risedronate—osteoporosis	0.000202	0.000539	CcSEcCtD
Gliclazide—Eye disorder—Estradiol—osteoporosis	0.000202	0.000539	CcSEcCtD
Gliclazide—Tinnitus—Estradiol—osteoporosis	0.000202	0.000538	CcSEcCtD
Gliclazide—Constipation—Ethinyl Estradiol—osteoporosis	0.000201	0.000537	CcSEcCtD
Gliclazide—Confusional state—Zoledronate—osteoporosis	0.000201	0.000536	CcSEcCtD
Gliclazide—Hypersensitivity—Calcitriol—osteoporosis	0.000201	0.000536	CcSEcCtD
Gliclazide—Flushing—Estradiol—osteoporosis	0.000201	0.000535	CcSEcCtD
Gliclazide—Arthralgia—Conjugated Estrogens—osteoporosis	0.0002	0.000534	CcSEcCtD
Gliclazide—Myalgia—Conjugated Estrogens—osteoporosis	0.0002	0.000534	CcSEcCtD
Gliclazide—Chest pain—Conjugated Estrogens—osteoporosis	0.0002	0.000534	CcSEcCtD
Gliclazide—Asthenia—Ibandronate—osteoporosis	0.0002	0.000533	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—GPD2—osteoporosis	0.0002	0.00126	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PGLS—osteoporosis	0.0002	0.00126	CbGpPWpGaD
Gliclazide—Anxiety—Conjugated Estrogens—osteoporosis	0.0002	0.000532	CcSEcCtD
Gliclazide—Nausea—Etidronic acid—osteoporosis	0.000199	0.000532	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000199	0.000531	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000199	0.000531	CcSEcCtD
Gliclazide—Diarrhoea—Estropipate—osteoporosis	0.000199	0.00053	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Risedronate—osteoporosis	0.000198	0.000529	CcSEcCtD
Gliclazide—Infection—Zoledronate—osteoporosis	0.000198	0.000528	CcSEcCtD
Gliclazide—Fatigue—Risedronate—osteoporosis	0.000198	0.000528	CcSEcCtD
Gliclazide—ALB—Hemostasis—WDR1—osteoporosis	0.000198	0.00125	CbGpPWpGaD
Gliclazide—Insomnia—Pamidronate—osteoporosis	0.000197	0.000527	CcSEcCtD
Gliclazide—Pruritus—Ibandronate—osteoporosis	0.000197	0.000526	CcSEcCtD
Gliclazide—Constipation—Risedronate—osteoporosis	0.000196	0.000524	CcSEcCtD
Gliclazide—Pain—Risedronate—osteoporosis	0.000196	0.000524	CcSEcCtD
Gliclazide—Paraesthesia—Pamidronate—osteoporosis	0.000196	0.000523	CcSEcCtD
Gliclazide—Diarrhoea—Alendronate—osteoporosis	0.000196	0.000522	CcSEcCtD
Gliclazide—Asthenia—Calcitriol—osteoporosis	0.000196	0.000522	CcSEcCtD
Gliclazide—Nervous system disorder—Zoledronate—osteoporosis	0.000195	0.000522	CcSEcCtD
Gliclazide—Thrombocytopenia—Zoledronate—osteoporosis	0.000195	0.000521	CcSEcCtD
Gliclazide—Dyspnoea—Pamidronate—osteoporosis	0.000195	0.000519	CcSEcCtD
Gliclazide—Tachycardia—Zoledronate—osteoporosis	0.000195	0.000519	CcSEcCtD
Gliclazide—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000194	0.000518	CcSEcCtD
Gliclazide—Chills—Estradiol—osteoporosis	0.000194	0.000518	CcSEcCtD
Gliclazide—Somnolence—Pamidronate—osteoporosis	0.000194	0.000518	CcSEcCtD
Gliclazide—Skin disorder—Zoledronate—osteoporosis	0.000194	0.000517	CcSEcCtD
Gliclazide—Pruritus—Calcitriol—osteoporosis	0.000193	0.000515	CcSEcCtD
Gliclazide—Hyperhidrosis—Zoledronate—osteoporosis	0.000193	0.000514	CcSEcCtD
Gliclazide—CYP2C9—Biological oxidations—CYP27A1—osteoporosis	0.000193	0.00121	CbGpPWpGaD
Gliclazide—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000193	0.000514	CcSEcCtD
Gliclazide—Diarrhoea—Raloxifene—osteoporosis	0.000192	0.000514	CcSEcCtD
Gliclazide—Dyspepsia—Pamidronate—osteoporosis	0.000192	0.000513	CcSEcCtD
Gliclazide—Dizziness—Estropipate—osteoporosis	0.000192	0.000513	CcSEcCtD
Gliclazide—Infection—Conjugated Estrogens—osteoporosis	0.000191	0.000509	CcSEcCtD
Gliclazide—Diarrhoea—Ibandronate—osteoporosis	0.000191	0.000509	CcSEcCtD
Gliclazide—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.00019	0.0012	CbGpPWpGaD
Gliclazide—CYP2C9—Metapathway biotransformation—CYP27A1—osteoporosis	0.00019	0.0012	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—TLN1—osteoporosis	0.00019	0.0012	CbGpPWpGaD
Gliclazide—Mental disorder—Estradiol—osteoporosis	0.000189	0.000505	CcSEcCtD
Gliclazide—Dizziness—Alendronate—osteoporosis	0.000189	0.000505	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—FGB—osteoporosis	0.000189	0.00119	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ATIC—osteoporosis	0.000188	0.00119	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PNP—osteoporosis	0.000188	0.00119	CbGpPWpGaD
Gliclazide—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000188	0.000503	CcSEcCtD
Gliclazide—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000188	0.000502	CcSEcCtD
Gliclazide—Malnutrition—Estradiol—osteoporosis	0.000188	0.000502	CcSEcCtD
Gliclazide—Erythema—Estradiol—osteoporosis	0.000188	0.000502	CcSEcCtD
Gliclazide—Fatigue—Pamidronate—osteoporosis	0.000188	0.000502	CcSEcCtD
Gliclazide—Gastrointestinal pain—Risedronate—osteoporosis	0.000188	0.000501	CcSEcCtD
Gliclazide—ALB—Platelet activation, signaling and aggregation—VCL—osteoporosis	0.000187	0.00118	CbGpPWpGaD
Gliclazide—Tachycardia—Conjugated Estrogens—osteoporosis	0.000187	0.0005	CcSEcCtD
Gliclazide—Urticaria—Ethinyl Estradiol—osteoporosis	0.000187	0.000499	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—IGF1—osteoporosis	0.000187	0.00118	CbGpPWpGaD
Gliclazide—Constipation—Pamidronate—osteoporosis	0.000187	0.000498	CcSEcCtD
Gliclazide—Pain—Pamidronate—osteoporosis	0.000187	0.000498	CcSEcCtD
Gliclazide—Diarrhoea—Calcitriol—osteoporosis	0.000187	0.000498	CcSEcCtD
Gliclazide—Skin disorder—Conjugated Estrogens—osteoporosis	0.000186	0.000497	CcSEcCtD
Gliclazide—Hypotension—Zoledronate—osteoporosis	0.000186	0.000497	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	0.000186	0.00117	CbGpPWpGaD
Gliclazide—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000186	0.000497	CcSEcCtD
Gliclazide—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000186	0.000497	CcSEcCtD
Gliclazide—Dizziness—Raloxifene—osteoporosis	0.000186	0.000497	CcSEcCtD
Gliclazide—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000186	0.000495	CcSEcCtD
Gliclazide—Flatulence—Estradiol—osteoporosis	0.000185	0.000495	CcSEcCtD
Gliclazide—Tension—Estradiol—osteoporosis	0.000185	0.000493	CcSEcCtD
Gliclazide—Vomiting—Estropipate—osteoporosis	0.000185	0.000493	CcSEcCtD
Gliclazide—Dizziness—Ibandronate—osteoporosis	0.000184	0.000492	CcSEcCtD
Gliclazide—Rash—Estropipate—osteoporosis	0.000183	0.000489	CcSEcCtD
Gliclazide—Dermatitis—Estropipate—osteoporosis	0.000183	0.000488	CcSEcCtD
Gliclazide—Nervousness—Estradiol—osteoporosis	0.000183	0.000488	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—ATIC—osteoporosis	0.000183	0.00115	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PNP—osteoporosis	0.000183	0.00115	CbGpPWpGaD
Gliclazide—Urticaria—Risedronate—osteoporosis	0.000182	0.000487	CcSEcCtD
Gliclazide—Back pain—Estradiol—osteoporosis	0.000182	0.000486	CcSEcCtD
Gliclazide—Headache—Estropipate—osteoporosis	0.000182	0.000486	CcSEcCtD
Gliclazide—Vomiting—Alendronate—osteoporosis	0.000182	0.000485	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000182	0.000485	CcSEcCtD
Gliclazide—Body temperature increased—Risedronate—osteoporosis	0.000181	0.000484	CcSEcCtD
Gliclazide—Abdominal pain—Risedronate—osteoporosis	0.000181	0.000484	CcSEcCtD
Gliclazide—Rash—Alendronate—osteoporosis	0.00018	0.000481	CcSEcCtD
Gliclazide—ALB—Selenium Micronutrient Network—SOD2—osteoporosis	0.00018	0.00114	CbGpPWpGaD
Gliclazide—Insomnia—Zoledronate—osteoporosis	0.00018	0.000481	CcSEcCtD
Gliclazide—Dermatitis—Alendronate—osteoporosis	0.00018	0.000481	CcSEcCtD
Gliclazide—Feeling abnormal—Pamidronate—osteoporosis	0.00018	0.00048	CcSEcCtD
Gliclazide—Hypotension—Conjugated Estrogens—osteoporosis	0.000179	0.000479	CcSEcCtD
Gliclazide—Headache—Alendronate—osteoporosis	0.000179	0.000478	CcSEcCtD
Gliclazide—Paraesthesia—Zoledronate—osteoporosis	0.000179	0.000478	CcSEcCtD
Gliclazide—Vomiting—Raloxifene—osteoporosis	0.000179	0.000477	CcSEcCtD
Gliclazide—Gastrointestinal pain—Pamidronate—osteoporosis	0.000178	0.000476	CcSEcCtD
Gliclazide—Dyspnoea—Zoledronate—osteoporosis	0.000178	0.000474	CcSEcCtD
Gliclazide—Rash—Raloxifene—osteoporosis	0.000177	0.000473	CcSEcCtD
Gliclazide—Dermatitis—Raloxifene—osteoporosis	0.000177	0.000473	CcSEcCtD
Gliclazide—Somnolence—Zoledronate—osteoporosis	0.000177	0.000473	CcSEcCtD
Gliclazide—Vomiting—Ibandronate—osteoporosis	0.000177	0.000473	CcSEcCtD
Gliclazide—Tremor—Estradiol—osteoporosis	0.000176	0.000471	CcSEcCtD
Gliclazide—Headache—Raloxifene—osteoporosis	0.000176	0.00047	CcSEcCtD
Gliclazide—Rash—Ibandronate—osteoporosis	0.000176	0.000469	CcSEcCtD
Gliclazide—Dermatitis—Ibandronate—osteoporosis	0.000175	0.000468	CcSEcCtD
Gliclazide—Dyspepsia—Zoledronate—osteoporosis	0.000175	0.000468	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000175	0.000467	CcSEcCtD
Gliclazide—Ill-defined disorder—Estradiol—osteoporosis	0.000175	0.000466	CcSEcCtD
Gliclazide—Headache—Ibandronate—osteoporosis	0.000174	0.000466	CcSEcCtD
Gliclazide—Insomnia—Conjugated Estrogens—osteoporosis	0.000174	0.000463	CcSEcCtD
Gliclazide—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000173	0.000463	CcSEcCtD
Gliclazide—Vomiting—Calcitriol—osteoporosis	0.000173	0.000463	CcSEcCtD
Gliclazide—Agitation—Estradiol—osteoporosis	0.000173	0.000462	CcSEcCtD
Gliclazide—Nausea—Estropipate—osteoporosis	0.000173	0.00046	CcSEcCtD
Gliclazide—Abdominal pain—Pamidronate—osteoporosis	0.000172	0.00046	CcSEcCtD
Gliclazide—Body temperature increased—Pamidronate—osteoporosis	0.000172	0.00046	CcSEcCtD
Gliclazide—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000172	0.00046	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000172	0.000459	CcSEcCtD
Gliclazide—ALB—Selenium Micronutrient Network—GPX1—osteoporosis	0.000172	0.00108	CbGpPWpGaD
Gliclazide—Angioedema—Estradiol—osteoporosis	0.000172	0.000459	CcSEcCtD
Gliclazide—Rash—Calcitriol—osteoporosis	0.000172	0.000459	CcSEcCtD
Gliclazide—Fatigue—Zoledronate—osteoporosis	0.000172	0.000459	CcSEcCtD
Gliclazide—Dermatitis—Calcitriol—osteoporosis	0.000172	0.000458	CcSEcCtD
Gliclazide—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000171	0.000457	CcSEcCtD
Gliclazide—Headache—Calcitriol—osteoporosis	0.000171	0.000456	CcSEcCtD
Gliclazide—Somnolence—Conjugated Estrogens—osteoporosis	0.000171	0.000455	CcSEcCtD
Gliclazide—Pain—Zoledronate—osteoporosis	0.00017	0.000455	CcSEcCtD
Gliclazide—Constipation—Zoledronate—osteoporosis	0.00017	0.000455	CcSEcCtD
Gliclazide—Nausea—Alendronate—osteoporosis	0.00017	0.000453	CcSEcCtD
Gliclazide—Malaise—Estradiol—osteoporosis	0.00017	0.000453	CcSEcCtD
Gliclazide—Hypersensitivity—Risedronate—osteoporosis	0.000169	0.000451	CcSEcCtD
Gliclazide—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000169	0.000451	CcSEcCtD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—IL1B—osteoporosis	0.000169	0.00106	CbGpPWpGaD
Gliclazide—Asthenia—Ethinyl Estradiol—osteoporosis	0.000169	0.000451	CcSEcCtD
Gliclazide—Nausea—Raloxifene—osteoporosis	0.000167	0.000446	CcSEcCtD
Gliclazide—Pruritus—Ethinyl Estradiol—osteoporosis	0.000167	0.000445	CcSEcCtD
Gliclazide—Palpitations—Estradiol—osteoporosis	0.000166	0.000444	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—SOST—osteoporosis	0.000166	0.00105	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—IGF1—osteoporosis	0.000166	0.00104	CbGpPWpGaD
Gliclazide—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000166	0.000442	CcSEcCtD
Gliclazide—Fatigue—Conjugated Estrogens—osteoporosis	0.000165	0.000442	CcSEcCtD
Gliclazide—Nausea—Ibandronate—osteoporosis	0.000165	0.000442	CcSEcCtD
Gliclazide—Loss of consciousness—Estradiol—osteoporosis	0.000165	0.000441	CcSEcCtD
Gliclazide—Asthenia—Risedronate—osteoporosis	0.000165	0.00044	CcSEcCtD
Gliclazide—Feeling abnormal—Zoledronate—osteoporosis	0.000164	0.000438	CcSEcCtD
Gliclazide—Cough—Estradiol—osteoporosis	0.000164	0.000438	CcSEcCtD
Gliclazide—Constipation—Conjugated Estrogens—osteoporosis	0.000164	0.000438	CcSEcCtD
Gliclazide—Pain—Conjugated Estrogens—osteoporosis	0.000164	0.000438	CcSEcCtD
Gliclazide—Gastrointestinal pain—Zoledronate—osteoporosis	0.000163	0.000435	CcSEcCtD
Gliclazide—Hypertension—Estradiol—osteoporosis	0.000162	0.000434	CcSEcCtD
Gliclazide—Pruritus—Risedronate—osteoporosis	0.000162	0.000433	CcSEcCtD
Gliclazide—Nausea—Calcitriol—osteoporosis	0.000162	0.000432	CcSEcCtD
Gliclazide—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000161	0.00043	CcSEcCtD
Gliclazide—Hypersensitivity—Pamidronate—osteoporosis	0.000161	0.000429	CcSEcCtD
Gliclazide—Chest pain—Estradiol—osteoporosis	0.00016	0.000428	CcSEcCtD
Gliclazide—Arthralgia—Estradiol—osteoporosis	0.00016	0.000428	CcSEcCtD
Gliclazide—Myalgia—Estradiol—osteoporosis	0.00016	0.000428	CcSEcCtD
Gliclazide—ABCC8—Metabolism—OXCT1—osteoporosis	0.00016	0.00101	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CA2—osteoporosis	0.00016	0.00101	CbGpPWpGaD
Gliclazide—Anxiety—Estradiol—osteoporosis	0.00016	0.000426	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000159	0.000425	CcSEcCtD
Gliclazide—ALB—Selenium Micronutrient Network—MTHFR—osteoporosis	0.000159	0.001	CbGpPWpGaD
Gliclazide—Urticaria—Zoledronate—osteoporosis	0.000158	0.000423	CcSEcCtD
Gliclazide—Discomfort—Estradiol—osteoporosis	0.000158	0.000422	CcSEcCtD
Gliclazide—Body temperature increased—Zoledronate—osteoporosis	0.000158	0.00042	CcSEcCtD
Gliclazide—Abdominal pain—Zoledronate—osteoporosis	0.000158	0.00042	CcSEcCtD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.000157	0.000992	CbGpPWpGaD
Gliclazide—Diarrhoea—Risedronate—osteoporosis	0.000157	0.000419	CcSEcCtD
Gliclazide—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000157	0.000419	CcSEcCtD
Gliclazide—Dry mouth—Estradiol—osteoporosis	0.000157	0.000418	CcSEcCtD
Gliclazide—Asthenia—Pamidronate—osteoporosis	0.000157	0.000418	CcSEcCtD
Gliclazide—ALB—Platelet activation, signaling and aggregation—RAP1A—osteoporosis	0.000157	0.000987	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—CAP1—osteoporosis	0.000156	0.000985	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—MGLL—osteoporosis	0.000156	0.000984	CbGpPWpGaD
Gliclazide—Dizziness—Ethinyl Estradiol—osteoporosis	0.000156	0.000415	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—CA2—osteoporosis	0.000155	0.000979	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—OXCT1—osteoporosis	0.000155	0.000979	CbGpPWpGaD
Gliclazide—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.000155	0.000976	CbGpPWpGaD
Gliclazide—Confusional state—Estradiol—osteoporosis	0.000155	0.000413	CcSEcCtD
Gliclazide—Pruritus—Pamidronate—osteoporosis	0.000154	0.000412	CcSEcCtD
Gliclazide—Infection—Estradiol—osteoporosis	0.000153	0.000407	CcSEcCtD
Gliclazide—Urticaria—Conjugated Estrogens—osteoporosis	0.000152	0.000407	CcSEcCtD
Gliclazide—Dizziness—Risedronate—osteoporosis	0.000152	0.000405	CcSEcCtD
Gliclazide—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000152	0.000405	CcSEcCtD
Gliclazide—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000152	0.000405	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—MGLL—osteoporosis	0.000151	0.000954	CbGpPWpGaD
Gliclazide—Nervous system disorder—Estradiol—osteoporosis	0.000151	0.000402	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—CALCR—osteoporosis	0.00015	0.000946	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PTH1R—osteoporosis	0.00015	0.000946	CbGpPWpGaD
Gliclazide—Tachycardia—Estradiol—osteoporosis	0.00015	0.0004	CcSEcCtD
Gliclazide—Vomiting—Ethinyl Estradiol—osteoporosis	0.00015	0.000399	CcSEcCtD
Gliclazide—Diarrhoea—Pamidronate—osteoporosis	0.000149	0.000398	CcSEcCtD
Gliclazide—Skin disorder—Estradiol—osteoporosis	0.000149	0.000398	CcSEcCtD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.000149	0.00094	CbGpPWpGaD
Gliclazide—Hyperhidrosis—Estradiol—osteoporosis	0.000148	0.000396	CcSEcCtD
Gliclazide—Rash—Ethinyl Estradiol—osteoporosis	0.000148	0.000396	CcSEcCtD
Gliclazide—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000148	0.000396	CcSEcCtD
Gliclazide—Headache—Ethinyl Estradiol—osteoporosis	0.000147	0.000394	CcSEcCtD
Gliclazide—Hypersensitivity—Zoledronate—osteoporosis	0.000147	0.000392	CcSEcCtD
Gliclazide—Vomiting—Risedronate—osteoporosis	0.000146	0.000389	CcSEcCtD
Gliclazide—ALB—Vitamin B12 Metabolism—IL1B—osteoporosis	0.000146	0.000919	CbGpPWpGaD
Gliclazide—Rash—Risedronate—osteoporosis	0.000145	0.000386	CcSEcCtD
Gliclazide—Dermatitis—Risedronate—osteoporosis	0.000145	0.000386	CcSEcCtD
Gliclazide—Dizziness—Pamidronate—osteoporosis	0.000144	0.000385	CcSEcCtD
Gliclazide—Headache—Risedronate—osteoporosis	0.000144	0.000384	CcSEcCtD
Gliclazide—Asthenia—Zoledronate—osteoporosis	0.000143	0.000382	CcSEcCtD
Gliclazide—ALB—Platelet activation, signaling and aggregation—FGA—osteoporosis	0.000142	0.000895	CbGpPWpGaD
Gliclazide—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000141	0.000377	CcSEcCtD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.000141	0.00089	CbGpPWpGaD
Gliclazide—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.000141	0.00089	CbGpPWpGaD
Gliclazide—Pruritus—Zoledronate—osteoporosis	0.000141	0.000376	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Estradiol—osteoporosis	0.00014	0.000373	CcSEcCtD
Gliclazide—Nausea—Ethinyl Estradiol—osteoporosis	0.00014	0.000373	CcSEcCtD
Gliclazide—Insomnia—Estradiol—osteoporosis	0.000139	0.000371	CcSEcCtD
Gliclazide—Vomiting—Pamidronate—osteoporosis	0.000139	0.00037	CcSEcCtD
Gliclazide—Paraesthesia—Estradiol—osteoporosis	0.000138	0.000368	CcSEcCtD
Gliclazide—Asthenia—Conjugated Estrogens—osteoporosis	0.000138	0.000367	CcSEcCtD
Gliclazide—Rash—Pamidronate—osteoporosis	0.000138	0.000367	CcSEcCtD
Gliclazide—Dermatitis—Pamidronate—osteoporosis	0.000137	0.000367	CcSEcCtD
Gliclazide—Dyspnoea—Estradiol—osteoporosis	0.000137	0.000365	CcSEcCtD
Gliclazide—Headache—Pamidronate—osteoporosis	0.000137	0.000365	CcSEcCtD
Gliclazide—Somnolence—Estradiol—osteoporosis	0.000137	0.000364	CcSEcCtD
Gliclazide—Diarrhoea—Zoledronate—osteoporosis	0.000136	0.000364	CcSEcCtD
Gliclazide—Nausea—Risedronate—osteoporosis	0.000136	0.000364	CcSEcCtD
Gliclazide—Pruritus—Conjugated Estrogens—osteoporosis	0.000136	0.000362	CcSEcCtD
Gliclazide—Dyspepsia—Estradiol—osteoporosis	0.000135	0.000361	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—MYC—osteoporosis	0.000135	0.000851	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.000134	0.000844	CbGpPWpGaD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—IL6—osteoporosis	0.000134	0.000843	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—IDH2—osteoporosis	0.000133	0.000837	CbGpPWpGaD
Gliclazide—Gastrointestinal disorder—Estradiol—osteoporosis	0.000133	0.000354	CcSEcCtD
Gliclazide—Fatigue—Estradiol—osteoporosis	0.000132	0.000353	CcSEcCtD
Gliclazide—ALB—Platelet degranulation—IGF1—osteoporosis	0.000132	0.000831	CbGpPWpGaD
Gliclazide—Dizziness—Zoledronate—osteoporosis	0.000132	0.000352	CcSEcCtD
Gliclazide—Pain—Estradiol—osteoporosis	0.000131	0.000351	CcSEcCtD
Gliclazide—Constipation—Estradiol—osteoporosis	0.000131	0.000351	CcSEcCtD
Gliclazide—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000131	0.00035	CcSEcCtD
Gliclazide—Nausea—Pamidronate—osteoporosis	0.00013	0.000346	CcSEcCtD
Gliclazide—ALB—Platelet activation, signaling and aggregation—FGB—osteoporosis	0.000129	0.000814	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.000129	0.000812	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—IDH2—osteoporosis	0.000129	0.000811	CbGpPWpGaD
Gliclazide—Dizziness—Conjugated Estrogens—osteoporosis	0.000127	0.000339	CcSEcCtD
Gliclazide—Vomiting—Zoledronate—osteoporosis	0.000127	0.000338	CcSEcCtD
Gliclazide—Feeling abnormal—Estradiol—osteoporosis	0.000127	0.000338	CcSEcCtD
Gliclazide—VEGFA—Signaling by VEGF—IL6—osteoporosis	0.000126	0.000796	CbGpPWpGaD
Gliclazide—Rash—Zoledronate—osteoporosis	0.000126	0.000335	CcSEcCtD
Gliclazide—Gastrointestinal pain—Estradiol—osteoporosis	0.000126	0.000335	CcSEcCtD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—IGF1—osteoporosis	0.000126	0.000792	CbGpPWpGaD
Gliclazide—CYP2C19—Phase 1 - Functionalization of compounds—POMC—osteoporosis	0.000126	0.000791	CbGpPWpGaD
Gliclazide—Dermatitis—Zoledronate—osteoporosis	0.000126	0.000335	CcSEcCtD
Gliclazide—Headache—Zoledronate—osteoporosis	0.000125	0.000333	CcSEcCtD
Gliclazide—ABCC8—Metabolism—CYP27A1—osteoporosis	0.000125	0.000787	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—MGLL—osteoporosis	0.000124	0.000783	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—IL6R—osteoporosis	0.000124	0.00078	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—TNF—osteoporosis	0.000123	0.000773	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.000122	0.00077	CbGpPWpGaD
Gliclazide—Vomiting—Conjugated Estrogens—osteoporosis	0.000122	0.000326	CcSEcCtD
Gliclazide—Urticaria—Estradiol—osteoporosis	0.000122	0.000326	CcSEcCtD
Gliclazide—Body temperature increased—Estradiol—osteoporosis	0.000121	0.000324	CcSEcCtD
Gliclazide—Abdominal pain—Estradiol—osteoporosis	0.000121	0.000324	CcSEcCtD
Gliclazide—ABCC8—Metabolism—ACP5—osteoporosis	0.000121	0.000765	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CYP27A1—osteoporosis	0.000121	0.000763	CbGpPWpGaD
Gliclazide—Rash—Conjugated Estrogens—osteoporosis	0.000121	0.000323	CcSEcCtD
Gliclazide—Dermatitis—Conjugated Estrogens—osteoporosis	0.000121	0.000323	CcSEcCtD
Gliclazide—Headache—Conjugated Estrogens—osteoporosis	0.00012	0.000321	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—MGLL—osteoporosis	0.000119	0.000752	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—IL1B—osteoporosis	0.000119	0.000748	CbGpPWpGaD
Gliclazide—Nausea—Zoledronate—osteoporosis	0.000118	0.000316	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—ACP5—osteoporosis	0.000118	0.000742	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—LRP5—osteoporosis	0.000116	0.000734	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	0.000116	0.000731	CbGpPWpGaD
Gliclazide—CYP2C9—Phase 1 - Functionalization of compounds—POMC—osteoporosis	0.000114	0.000722	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—ADCY5—osteoporosis	0.000114	0.000721	CbGpPWpGaD
Gliclazide—Nausea—Conjugated Estrogens—osteoporosis	0.000114	0.000304	CcSEcCtD
Gliclazide—ALB—Hemostasis—PLEK—osteoporosis	0.000114	0.000716	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—ANXA2—osteoporosis	0.000114	0.000716	CbGpPWpGaD
Gliclazide—Hypersensitivity—Estradiol—osteoporosis	0.000113	0.000302	CcSEcCtD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	0.000113	0.000713	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—TPI1—osteoporosis	0.000113	0.000712	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	0.000112	0.000705	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	0.000112	0.000704	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—LRP6—osteoporosis	0.000111	0.000702	CbGpPWpGaD
Gliclazide—CYP2C19—Biological oxidations—CYP19A1—osteoporosis	0.000111	0.0007	CbGpPWpGaD
Gliclazide—Asthenia—Estradiol—osteoporosis	0.00011	0.000294	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—TPI1—osteoporosis	0.000109	0.00069	CbGpPWpGaD
Gliclazide—CYP2C19—Metapathway biotransformation—CYP19A1—osteoporosis	0.000109	0.00069	CbGpPWpGaD
Gliclazide—Pruritus—Estradiol—osteoporosis	0.000109	0.00029	CcSEcCtD
Gliclazide—ABCC8—Metabolism—P4HB—osteoporosis	0.000106	0.000669	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—TNF—osteoporosis	0.000106	0.000667	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—LEP—osteoporosis	0.000105	0.000664	CbGpPWpGaD
Gliclazide—Diarrhoea—Estradiol—osteoporosis	0.000105	0.00028	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	0.000104	0.000657	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—GAPDH—osteoporosis	0.000104	0.000657	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	0.000104	0.000656	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—P4HB—osteoporosis	0.000103	0.000649	CbGpPWpGaD
Gliclazide—Dizziness—Estradiol—osteoporosis	0.000102	0.000271	CcSEcCtD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	0.000101	0.00064	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—RAP1A—osteoporosis	0.000101	0.00064	CbGpPWpGaD
Gliclazide—CYP2C9—Biological oxidations—CYP19A1—osteoporosis	0.000101	0.000638	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GAPDH—osteoporosis	0.000101	0.000637	CbGpPWpGaD
Gliclazide—CYP2C9—Metapathway biotransformation—CYP19A1—osteoporosis	9.98e-05	0.000629	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—TGFB1—osteoporosis	9.93e-05	0.000626	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—IL6—osteoporosis	9.89e-05	0.000623	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—RAP1A—osteoporosis	9.84e-05	0.00062	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—ANXA2—osteoporosis	9.83e-05	0.00062	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TLN1—osteoporosis	9.79e-05	0.000617	CbGpPWpGaD
Gliclazide—Vomiting—Estradiol—osteoporosis	9.77e-05	0.000261	CcSEcCtD
Gliclazide—Rash—Estradiol—osteoporosis	9.68e-05	0.000258	CcSEcCtD
Gliclazide—Dermatitis—Estradiol—osteoporosis	9.68e-05	0.000258	CcSEcCtD
Gliclazide—ALB—Hemostasis—VCL—osteoporosis	9.66e-05	0.000609	CbGpPWpGaD
Gliclazide—Headache—Estradiol—osteoporosis	9.62e-05	0.000257	CcSEcCtD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	9.49e-05	0.000598	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—IL1B—osteoporosis	9.42e-05	0.000594	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TLN1—osteoporosis	9.4e-05	0.000593	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	9.25e-05	0.000583	CbGpPWpGaD
Gliclazide—Nausea—Estradiol—osteoporosis	9.12e-05	0.000243	CcSEcCtD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	9.04e-05	0.00057	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—IL6R—osteoporosis	8.83e-05	0.000557	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—TNF—osteoporosis	8.61e-05	0.000543	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—IGF1—osteoporosis	8.54e-05	0.000538	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—IL6—osteoporosis	8.54e-05	0.000538	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ENO1—osteoporosis	8.2e-05	0.000517	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	8.11e-05	0.000511	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—P4HB—osteoporosis	8.11e-05	0.000511	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PSMA5—osteoporosis	8.08e-05	0.000509	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PSMA2—osteoporosis	8.08e-05	0.000509	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—RAP1A—osteoporosis	8.07e-05	0.000509	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ENO1—osteoporosis	7.95e-05	0.000501	CbGpPWpGaD
Gliclazide—ALB—Platelet degranulation—TGFB1—osteoporosis	7.9e-05	0.000498	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PTH—osteoporosis	7.89e-05	0.000497	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PSMA2—osteoporosis	7.84e-05	0.000494	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PSMA5—osteoporosis	7.84e-05	0.000494	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—RAP1A—osteoporosis	7.75e-05	0.000489	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CNR2—osteoporosis	7.69e-05	0.000484	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	7.68e-05	0.000484	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NFATC1—osteoporosis	7.56e-05	0.000477	CbGpPWpGaD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—osteoporosis	7.53e-05	0.000475	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—DKK1—osteoporosis	7.5e-05	0.000473	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	7.4e-05	0.000466	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—FGA—osteoporosis	7.32e-05	0.000461	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—WNT1—osteoporosis	7.23e-05	0.000456	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—FGA—osteoporosis	7.03e-05	0.000443	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PKM—osteoporosis	7.01e-05	0.000442	CbGpPWpGaD
Gliclazide—ALB—Metabolism—FDPS—osteoporosis	7.01e-05	0.000442	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—IL6—osteoporosis	6.95e-05	0.000438	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	6.9e-05	0.000435	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—TNF—osteoporosis	6.84e-05	0.000431	CbGpPWpGaD
Gliclazide—CYP2C19—Biological oxidations—POMC—osteoporosis	6.67e-05	0.00042	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—FGB—osteoporosis	6.66e-05	0.00042	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PGLS—osteoporosis	6.64e-05	0.000419	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GPD2—osteoporosis	6.64e-05	0.000419	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CYP19A1—osteoporosis	6.56e-05	0.000413	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PTHLH—osteoporosis	6.54e-05	0.000412	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—BMP2—osteoporosis	6.54e-05	0.000412	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—IL6—osteoporosis	6.49e-05	0.000409	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—FGB—osteoporosis	6.4e-05	0.000403	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CYP19A1—osteoporosis	6.36e-05	0.000401	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PKM—osteoporosis	6.29e-05	0.000396	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—FDPS—osteoporosis	6.29e-05	0.000396	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	6.29e-05	0.000396	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PSMA2—osteoporosis	6.17e-05	0.000389	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PSMA5—osteoporosis	6.17e-05	0.000389	CbGpPWpGaD
Gliclazide—CYP2C9—Biological oxidations—POMC—osteoporosis	6.08e-05	0.000383	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PNP—osteoporosis	6.08e-05	0.000383	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ATIC—osteoporosis	6.08e-05	0.000383	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GPD2—osteoporosis	5.96e-05	0.000376	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PGLS—osteoporosis	5.96e-05	0.000376	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—IGF1—osteoporosis	5.85e-05	0.000369	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CALCA—osteoporosis	5.75e-05	0.000363	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—FDPS—osteoporosis	5.74e-05	0.000362	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PKM—osteoporosis	5.74e-05	0.000362	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—IL6—osteoporosis	5.52e-05	0.000348	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—IL6—osteoporosis	5.51e-05	0.000347	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PNP—osteoporosis	5.45e-05	0.000344	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ATIC—osteoporosis	5.45e-05	0.000344	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PGLS—osteoporosis	5.44e-05	0.000343	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GPD2—osteoporosis	5.44e-05	0.000343	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ADCY5—osteoporosis	5.36e-05	0.000338	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—GPX1—osteoporosis	5.34e-05	0.000337	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KL—osteoporosis	5.22e-05	0.000329	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—TGFB1—osteoporosis	5.22e-05	0.000329	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ADCY5—osteoporosis	5.19e-05	0.000327	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GPX1—osteoporosis	5.18e-05	0.000326	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CA2—osteoporosis	5.17e-05	0.000326	CbGpPWpGaD
Gliclazide—ALB—Metabolism—OXCT1—osteoporosis	5.17e-05	0.000326	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TGFB1—osteoporosis	5.12e-05	0.000323	CbGpPWpGaD
Gliclazide—ALB—Metabolism—MGLL—osteoporosis	5.03e-05	0.000317	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ATIC—osteoporosis	4.97e-05	0.000313	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PNP—osteoporosis	4.97e-05	0.000313	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—MTHFR—osteoporosis	4.93e-05	0.000311	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—TNF—osteoporosis	4.87e-05	0.000307	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—MTHFR—osteoporosis	4.78e-05	0.000301	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	4.75e-05	0.000299	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CA2—osteoporosis	4.64e-05	0.000292	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—OXCT1—osteoporosis	4.64e-05	0.000292	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—MGLL—osteoporosis	4.52e-05	0.000285	CbGpPWpGaD
Gliclazide—ALB—Metabolism—IDH2—osteoporosis	4.28e-05	0.00027	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	4.26e-05	0.000269	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—OXCT1—osteoporosis	4.23e-05	0.000267	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CA2—osteoporosis	4.23e-05	0.000267	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—MGLL—osteoporosis	4.12e-05	0.00026	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ADCY5—osteoporosis	4.09e-05	0.000258	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP27A1—osteoporosis	4.02e-05	0.000254	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SPP1—osteoporosis	3.96e-05	0.00025	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—POMC—osteoporosis	3.94e-05	0.000248	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—IL6—osteoporosis	3.93e-05	0.000248	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ACP5—osteoporosis	3.91e-05	0.000247	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	3.89e-05	0.000245	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	3.87e-05	0.000244	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—IDH2—osteoporosis	3.84e-05	0.000242	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—POMC—osteoporosis	3.82e-05	0.000241	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—ADCY5—osteoporosis	3.69e-05	0.000232	CbGpPWpGaD
Gliclazide—ALB—Metabolism—TPI1—osteoporosis	3.64e-05	0.000229	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP27A1—osteoporosis	3.61e-05	0.000228	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IRS2—osteoporosis	3.58e-05	0.000226	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ACP5—osteoporosis	3.51e-05	0.000222	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—TGFB1—osteoporosis	3.51e-05	0.000221	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—LEP—osteoporosis	3.5e-05	0.000221	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—IDH2—osteoporosis	3.5e-05	0.000221	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	3.47e-05	0.000219	CbGpPWpGaD
Gliclazide—ALB—Metabolism—P4HB—osteoporosis	3.42e-05	0.000216	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GAPDH—osteoporosis	3.36e-05	0.000212	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ESR1—osteoporosis	3.35e-05	0.000211	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP27A1—osteoporosis	3.29e-05	0.000208	CbGpPWpGaD
Gliclazide—ALB—Metabolism—RAP1A—osteoporosis	3.27e-05	0.000206	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—TPI1—osteoporosis	3.27e-05	0.000206	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ACP5—osteoporosis	3.2e-05	0.000202	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	3.16e-05	0.000199	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IRS1—osteoporosis	3.13e-05	0.000197	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—P4HB—osteoporosis	3.07e-05	0.000194	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GAPDH—osteoporosis	3.02e-05	0.00019	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IGF1—osteoporosis	3.01e-05	0.00019	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—POMC—osteoporosis	3.01e-05	0.00019	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—TPI1—osteoporosis	2.98e-05	0.000188	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—RAP1A—osteoporosis	2.94e-05	0.000185	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL6R—osteoporosis	2.94e-05	0.000185	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IGF1—osteoporosis	2.9e-05	0.000183	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—POMC—osteoporosis	2.85e-05	0.00018	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—P4HB—osteoporosis	2.8e-05	0.000177	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GAPDH—osteoporosis	2.75e-05	0.000173	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—RAP1A—osteoporosis	2.68e-05	0.000169	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ENO1—osteoporosis	2.64e-05	0.000167	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PSMA2—osteoporosis	2.61e-05	0.000164	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PSMA5—osteoporosis	2.61e-05	0.000164	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—osteoporosis	2.56e-05	0.000161	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ENO1—osteoporosis	2.37e-05	0.00015	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PSMA2—osteoporosis	2.34e-05	0.000147	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PSMA5—osteoporosis	2.34e-05	0.000147	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—osteoporosis	2.34e-05	0.000147	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ENO1—osteoporosis	2.16e-05	0.000136	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PSMA2—osteoporosis	2.13e-05	0.000134	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PSMA5—osteoporosis	2.13e-05	0.000134	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP19A1—osteoporosis	2.11e-05	0.000133	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP19A1—osteoporosis	1.9e-05	0.00012	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TGFB1—osteoporosis	1.81e-05	0.000114	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MYC—osteoporosis	1.74e-05	0.00011	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TGFB1—osteoporosis	1.74e-05	0.000109	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP19A1—osteoporosis	1.73e-05	0.000109	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ADCY5—osteoporosis	1.73e-05	0.000109	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GPX1—osteoporosis	1.72e-05	0.000109	CbGpPWpGaD
Gliclazide—ALB—Metabolism—MTHFR—osteoporosis	1.59e-05	0.0001	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ADCY5—osteoporosis	1.55e-05	9.77e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GPX1—osteoporosis	1.55e-05	9.74e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—MTHFR—osteoporosis	1.43e-05	8.99e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ADCY5—osteoporosis	1.41e-05	8.91e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GPX1—osteoporosis	1.41e-05	8.88e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL6—osteoporosis	1.31e-05	8.25e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—MTHFR—osteoporosis	1.3e-05	8.2e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—POMC—osteoporosis	1.27e-05	8.01e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—POMC—osteoporosis	1.14e-05	7.19e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—POMC—osteoporosis	1.04e-05	6.56e-05	CbGpPWpGaD
